| المؤلفون: |
Uslu, Ali1 (AUTHOR) zafersayin@gmail.com, Sayın, Zafer1 (AUTHOR) aslisakmanoglu@gmail.com, Balevi, Aslı1 (AUTHOR) oguzhandenizli@outlook.com, Gulcu, Yasin2 (AUTHOR) yasin.gulcu@tarimorman.gov.tr, Ergen, Fırat3 (AUTHOR) firatergen72@hotmail.com, Akıner, Islam2 (AUTHOR) 213146001001@lisansustu.selcuk.edu.tr, Denizli, Oguzhan1 (AUTHOR) erganis@selcuk.edu.tr, Erganis, Osman1 (AUTHOR) |
| مستخلص: |
Simple Summary: Brucella spp. is a bacteria that causes Brucellosis, a zoonotic disease that affects mammals, especially livestock. Since there is no effective vaccine for humans, controlling the disease in animals is vital. Although B. abortus S19, the first vaccine against bovine Brucellosis, cannot distinguish between the vaccinated and the infected like the vaccine strains studied in recent years, it is still used safely by various countries' eradication programs. The B. abortus S19 vaccine was initially administered subcutaneously at high doses, but studies have shown that reduced doses provide similar protection when administered conjunctively. In this study, vaccines from three companies were administered to calves via conjunctival and subcutaneous routes, and long-term antibody changes were monitored to clarify the differences in antibody titers created by different routes of administration and to use these differences to advantage in detecting infected animals and in screening times. Findings show that antibody titers resulting from subcutaneous vaccination may cause confusion in the detection of positive animals. On the other hand, conjunctival vaccines can contribute to the rapid, permanent control of Brucellosis in cattle thanks to their short-term and low antibody titer formation. However, conjunctival vaccine should not be combined with subcutaneous vaccination in eradication plans. Brucellosis is still the most common zoonosis worldwide despite advanced technology and animal husbandry. Since there is still no effective Brucella vaccine for humans, it is crucial to control the disease in ruminants through eradication and vaccination. Although some countries around the world have achieved this circumstance, every country aims to become free of Brucellosis through vaccination, animal movements, and various eradication measures. For this purpose, the Brucella abortus S19 strain has been used safely for about 100 years. However, due to the O-polysaccharide (OPS) antigen in its structure, the antibody response created by the vaccine causes confusion in serological tests. For this purpose, researchers have provided both mucosal immunity and short-term antibody response by using the B. abortus S19 vaccine in conjunctival form instead of subcutaneous form. This study aimed to determine how long the post-vaccination titer levels persisted in animals vaccinated with vaccines from 3 different companies and different routes. In this study, a total of 115 calves aged 3 to 4.5 months were created in five groups, with 23 animals in each group: group 1 (vaccine brand A), group 2 (vaccine brand B), and group 3 (vaccine brand C) received the two-dose conjunctival vaccine, group 4 received the single-dose subcutaneous vaccine (vaccine brand C), and group 5 received the subcutaneous vaccine (vaccine brand C) plus the booster dose conjunctival vaccine (vaccine brand B). Brucellosis antibody titers were monitored each 21 days until the cattle were 26–28 months old. The collected sera were analyzed using the Rose Bengal Plate Test (RBPT), Serum Agglutination Test (SAT), and Complement Fixation Test (CFT), which are the preferred serological methods for Brucellosis eradication plans worldwide. In the conjunctival vaccination groups, only 3 (13%) of the animals in group 1 developed antibody titers one month after vaccination, and there was no antibody response detected against Brucellosis in group 2 and group 3. In animals that were stimulated conjunctivally, the threshold value of 30 International CFT Units (ICFTUs) (for distinguishing between infective titers and vaccination titers) was observed in one animal each in group 1 and group 2 and 0 animal in group 3. It was found that antibody titers turn to Brucellosis negative in all conjunctival vaccine groups at 7 months after vaccination. In groups 4 and 5, the first-month serological screening detected over 30 ICFTUs in 17 (89.47%) animals and 16 (69.5%) animals, respectively. In group 4, CFT titers were found to fall below 30 on the 17th month and 9.3 on the 22nd month. On the 14th month, the CFT titers of group 5 were found to be below 30, and all animals in this group turned negative after the 19th month. It was found that the single dose B. abortus S19 subcutaneous vaccination in calves caused persistent antibodies in 5% of the population. It is believed that persistent and high antibody titers created by subcutaneous vaccines will cause false positivity and create confusion in Brucellosis eradication programs. Therefore, although there is no clear distinction between vaccinated and infected animals, it has been observed that conjunctival Brucellosis vaccines create more stable antibody titers and decrease rapidly compared to subcutaneous vaccines. Based on the results of this study and the advantages of conjunctival vaccines, more effective eradication programs and antibody monitoring can be carried out in vaccinated herds where Brucellosis outbreaks are observed. [ABSTRACT FROM AUTHOR] |
Full Text Finder